Alimera Sciences Q2 2024 Earnings Report

Alimera Sciences EPS Results

• Actual EPS: -$0.06
• Consensus EPS: -$0.04
• Beat/Miss: Missed by -$0.02
• One Year Ago EPS: N/A

Alimera Sciences Revenue Results

• Actual Revenue: $27.00 million
• Expected Revenue: $25.76 million
• Beat/Miss: Beat by +$1.24 million
• YoY Revenue Growth: N/A

Alimera Sciences Announcement Details

• Quarter: Q2 2024
• Date: 8/6/2024
• Time: TAS

Alimera Sciences (NASDAQ:ALIM), a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.